1
|
Mearin F, Caballero AM, Serra J, Brotons C, Tantiñà A, Fort E, Martínez-Cerezo FJ, Perelló A, Sánchez-Antolín G, Rey E, Angós Musgo R, Berdier R, Gómez-Rodríguez B, Clavé P, García-Alonso M, Torán-Monserrat P, Tack J. A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain. GASTROENTEROLOGIA Y HEPATOLOGIA 2019; 42:141-149. [PMID: 30612850 DOI: 10.1016/j.gastrohep.2018.10.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Revised: 10/15/2018] [Accepted: 10/24/2018] [Indexed: 12/18/2022]
Abstract
INTRODUCTION The socioeconomic burden of irritable bowel syndrome with constipation (IBS-C) has never been formally assessed in Spain. PATIENTS AND METHODS This 12-month (6-month retrospective and prospective periods) observational, multicentre study assessed the burden of moderate-to-severe IBS-C in Spain. Patients were included if they had been diagnosed with IBS-C (Rome III criteria) within the last 5 years and had moderate-to-severe IBS-C (IBS Symptom Severity Scale score [IBS-SSS] ≥175) at inclusion. The primary objective was to assess the direct cost to the Spanish healthcare system (HS). RESULTS A total of 112 patients were included, 64 (57%) of which had severe IBS-C at inclusion. At baseline, 89 (80%) patients reported abdominal pain and distention. Patient quality of life (QoL), measured by the IBS-C QoL and EQ-5D instruments, was found to be impaired with a mean score of 59 and 57 (0-100, worst-best), respectively. Over the 6-month prospective period the mean IBS-C severity, measured using the IBS-SSS showed some improvement (315-234 [0-500, best-worst]). During the year, 89 (80%) patients used prescription drugs for IBS-C, with laxatives being the most frequently prescribed (n=70; 63%). The direct cost to the HS was €1067, and to the patient was €568 per year. The total direct cost for moderate-to-severe IBS-C was €1635. DISCUSSION The majority of patients reported continuous IBS-C symptoms despite that 80% were taking medication to treat their IBS-C. Overall healthcare resource use and direct costs were asymmetric, with a small group of patients consuming the majority of resources.
Collapse
Affiliation(s)
| | | | - Jordi Serra
- Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - Carles Brotons
- Equip d'Atenció Primària Sardenya. Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), Barcelona, Spain
| | | | - Esther Fort
- Hospital Universitari Dr. Josep Trueta, Girona, Spain
| | | | | | | | - Enrique Rey
- Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
| | | | | | | | - Pere Clavé
- Hospital de Mataró, Mataró, Barcelona, Spain; Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
| | | | - Pere Torán-Monserrat
- Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mataró, Spain; Institut d'Investigació en Ciències de la Salut and Hospital Universitari Germans Trias i Pujol, Departament d'Atenció Primària, Badalona, Spain
| | - Jan Tack
- University of Leuven, Leuven, Belgium
| |
Collapse
|